Literature DB >> 29045135

Structural Basis of Inhibition of ERα-Coactivator Interaction by High-Affinity N-Terminus Isoaspartic Acid Tethered Helical Peptides.

Mingsheng Xie1, Hui Zhao1, Qisong Liu2, Yujia Zhu3, Feng Yin1, Yujie Liang1, Yanhong Jiang1, Dongyuan Wang1, Kuan Hu1, Xuan Qin1, Zichen Wang4, Yujie Wu5, Naihan Xu6, Xiyang Ye7, Tao Wang5, Zigang Li1.   

Abstract

Direct inhibition of the protein-protein interaction of ERα and its endogenous coactivators with a cell permeable stabilized peptide may offer a novel, promising strategy for combating ERα positive breast cancers. Here, we report the co-crystal structure of a helical peptide stabilized by a N-terminal unnatural cross-linked aspartic acid (TD) in complex with the ERα ligand binding domain (LBD). We designed a series of peptides and peptide 6 that showed direct and high-affinity binding to ERα with selective antiproliferative activity in ERα positive breast cancer cells. The co-crystal structure of the TD-stabilized peptide 6 in complex with ERα LBD further demonstrates that it forms an α helical conformation and directly binds at the coactivator binding site of ERα. Further studies showed that peptide 6W could potently inhibit cellular ERα's transcriptional activity. This approach demonstrates the potential of TD stabilized peptides to modulate various intracellular protein-protein interactions involved in a range of disorders.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29045135     DOI: 10.1021/acs.jmedchem.7b00732

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  A Cell-Permeable Stapled Peptide Inhibitor of the Estrogen Receptor/Coactivator Interaction.

Authors:  Thomas E Speltz; Jeanne M Danes; Joshua D Stender; Jonna Frasor; Terry W Moore
Journal:  ACS Chem Biol       Date:  2018-01-24       Impact factor: 5.100

2.  A "cross-stitched" peptide with improved helicity and proteolytic stability.

Authors:  Thomas E Speltz; Christopher G Mayne; Sean W Fanning; Zamia Siddiqui; Emad Tajkhorshid; Geoffrey L Greene; Terry W Moore
Journal:  Org Biomol Chem       Date:  2018-05-23       Impact factor: 3.876

3.  A VEGFR targeting peptide-drug conjugate (PDC) suppresses tumor angiogenesis in a TACE model for hepatocellular carcinoma therapy.

Authors:  Dongyuan Wang; Jiacheng Liu; Tongqiang Li; Yingliang Wang; Xiaoming Liu; Yaowei Bai; Chaoyang Wang; Shuguang Ju; Songjiang Huang; Chongtu Yang; Chen Zhou; Yu Zhang; Bin Xiong
Journal:  Cell Death Discov       Date:  2022-10-06

4.  Cytotoxic mixed-ligand complexes of Cu(II): A combined experimental and computational study.

Authors:  Mamaru Bitew Alem; Tadewos Damena; Tegene Desalegn; Moses Koobotse; Rajalakshmanan Eswaramoorthy; Kennedy J Ngwira; Japheth O Ombito; Matshediso Zachariah; Taye B Demissie
Journal:  Front Chem       Date:  2022-09-29       Impact factor: 5.545

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.